公开(公告)号：US11686730B2

公开(公告)日：2023-06-27

申请号：US17243502

申请日：2021-04-28

申请人： Quanterix Corporation

发明人： Andrew Ball ,  Lei Chang ,  Syrena Fernandes ,  Joe Johnson ,  Jeremy Lambert ,  Dawn Mattoon ,  Tatiana Plavina ,  David Wilson

IPC分类号： G01N33/569 ,  G01N33/567

CPC分类号： G01N33/56983 ,  G01N2333/165 ,  G01N2469/20

摘要： The present disclosure relates to methods and compositions, e.g., kits, for quantitatively detecting an antibody of a subject to an infectious organism. In some embodiments, the present disclosure provides for methods and compositions, e.g., kits, for quantitatively detecting a human antibody to SARS-CoV-2 polypeptide or S (spike) polypeptide. Certain applications and uses of the present methods and compositions, e.g., kits, are also provided.

公开(公告)号：US20230013244A1

公开(公告)日：2023-01-19

申请号：US17651064

申请日：2022-02-14

申请人： BioIncept, LLC

发明人： Eytan R. Barnea

IPC分类号： G01N33/564 ,  G01N33/569 ,  G01N33/68 ,  G01N33/567

摘要： Embodiments are directed to methods of examining preimplantation factor (PIF) binding to a subject's circulating immune cells as a marker for immune dysregulation. Some embodiments are directed to methods of detecting a level of immune dysregulation sufficient to cause recurrent pregnancy loss (RPL), methods of detecting a level of immune dysfunction sufficient to cause endometriosis, and methods of detecting a level of immune dysfunction comprising administering an effective amount of PIF or an analog thereof, and examining its binding to circulating immune cells. Within those methods, an about twenty percent change in PIF binding to a subject's circulating immune cells indicates a level of immune dysfunction.

公开(公告)号：US20220252593A1

公开(公告)日：2022-08-11

申请号：US17475098

申请日：2021-09-14

申请人： Alnylam Pharmaceuticals, Inc.

发明人： Brian Bettencourt

IPC分类号： G01N33/566 ,  C12N15/113 ,  C07D263/57 ,  G01N33/50 ,  G01N33/53 ,  G01N33/567 ,  G01N33/68

摘要： Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.

公开(公告)号：US20220099670A1

公开(公告)日：2022-03-31

申请号：US17427222

申请日：2021-01-31

申请人： Kyoto University ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Shin KANEKO ,  Shoichi IRIGUCHI ,  Keiko SEKIYA ,  Yoshiaki KASSAI

IPC分类号： G01N33/567 ,  C12N5/00 ,  C12N5/0784 ,  G01N33/50

摘要： Disclosed is a method for detecting regulatory dendritic cells, the method comprising step a: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step b: identifying regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Also disclosed is a method for producing a cell population enriched for regulatory dendritic cells, the method comprising step 1: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step 2: obtaining a cell population enriched for regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Further disclosed is a cell population enriched for regulatory dendritic cells obtained by the method.

公开(公告)号：US10890589B2

公开(公告)日：2021-01-12

申请号：US15313163

申请日：2015-05-27

申请人： GEORGETOWN UNIVERSITY ,  UNIVERSITY OF ROCHESTER

发明人： Massimo S. Fiandaca ,  Mark E. Mapstone ,  Howard J. Federoff ,  Xiaogang Zhong ,  Amrita K. Cheema

IPC分类号： A61K38/00 ,  C12Q1/68 ,  G01N33/567 ,  G01N33/68 ,  G01N33/92

摘要： The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

公开(公告)号：US10809271B2

公开(公告)日：2020-10-20

申请号：US15559001

申请日：2016-03-28

申请人： THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

发明人： Kendall Van Keuren-Jensen ,  Matthew Huentelman ,  Ashish Yeri

IPC分类号： A61K38/00 ,  C12Q1/68 ,  G01N33/567 ,  G01N33/68 ,  G16B20/00 ,  G16H50/30

摘要： The invention provides biomarkers and methods for determining the risk of a subject for developing mild traumatic brain injuries (mTBI). In some aspects, the methods of the invention also determine the fitness of a subject for participating in an activity with increased chances of receiving a head impact. Some embodiments of the invention are directed to kits for determining the risk of a subject for developing mTBI or the fitness of a subject for participating in an activity with increased chances of receiving a head impact.

公开(公告)号：US10739355B2

公开(公告)日：2020-08-11

申请号：US15543962

申请日：2016-11-15

申请人： Cambridge Enterprise Limited

发明人： Sabine Bahn ,  Jason Cooper ,  Frieder Haenisch

IPC分类号： A61K38/00 ,  C12Q1/68 ,  G01N33/567 ,  G01N33/68

摘要： The invention relates to biomarkers and methods of diagnosing or monitoring bipolar disorder, or a predisposition thereto.

公开(公告)号：US10732188B2

公开(公告)日：2020-08-04

申请号：US14291676

申请日：2014-05-30

申请人： Roche Diagnostics Operations, Inc.

发明人： Georg Hess ,  Andrea Horsch ,  Dietmar Zdunek

IPC分类号： A61K38/00 ,  C12Q1/68 ,  G01N33/567 ,  G01N33/74 ,  G01N33/68

摘要： The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.

公开(公告)号：US20190101533A1

公开(公告)日：2019-04-04

申请号：US16082946

申请日：2017-05-08

申请人： Northeast Ohio Medical University

发明人： Tariq M. HAQQI

IPC分类号： G01N33/567 ,  G01N33/564 ,  G01N33/573 ,  G01N33/50 ,  A01K67/027 ,  A61K38/45

摘要： A transgenic knockout non-human animal is described whose genome includes a heterozygous disruption of the expression of at least one endogenous gene encoding zinc-finger, CCHC domain-containing protein 6 (ZCCHC6). The transgenic animal model can be used to study bone disease or development by determining differences in bone characteristics, protein expression, or cytokine expression in the animal model in comparison to a corresponding wild-type non-human animal.

公开(公告)号：US10160800B2

公开(公告)日：2018-12-25

申请号：US15611416

申请日：2017-06-01

申请人： MedImmune Limited

发明人： Darren Schofield ,  Michael Perkinton ,  Lorraine Irving ,  George Thom

IPC分类号： A61K45/00 ,  G01N33/567 ,  A61P25/16 ,  A61P25/28 ,  C07K16/18 ,  G01N33/537 ,  G01N33/543 ,  G01N33/577 ,  G01N33/68 ,  A61K39/00

摘要： The invention provides antibodies that specifically bind human α-synuclein with a high affinity and reduces α-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating α-synuclein antibodies, and methods of using α-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.